A

AbbVie

Global biopharmaceutical company developing medicines

HR Business Partner

Full-TimePosted on 10/22/2026
No salary listed
Senior
Bachelor's
Sligo, Ireland
In Person
People & HRHR Generalist & Employee Relations

About the job

Requirements
  • A Level 8 degree in Human Resources, Business, Organisational Psychology, or a relevant discipline.
  • CIPD membership or an equivalent professional HR qualification.
  • Typically 6 or more years of progressive HR experience, including substantial HR Business Partner or senior HR generalist experience.
  • Strong working knowledge of Irish employment law and demonstrated experience managing complex employee relations matters.
  • Business acumen and ability to connect people priorities to operational, financial, quality, compliance, and growth outcomes.
  • Capability in organisation design, strategic workforce planning, talent management, succession, and change leadership.
  • Strong coaching, influencing, and facilitation skills, including confidence constructively challenging leaders.
  • Ability to interpret workforce and talent data, identify insights, and convert them into practical decisions and actions.
  • Sound judgement, risk awareness, project leadership, and ability to manage competing priorities with pace.
  • Enterprise mindset, learning agility, clarity and courage, accountability, and inclusive leadership.
Responsibilities
  • Own the day-to-day strategic partnership with assigned site leaders and functions, building trusted relationships and providing an independent people perspective to business decisions, with direction and guidance from the Business HR Manager.
  • Partner with leaders to shape, drive, and influence the site people strategy, translating site, Operations BHR, and enterprise priorities into workforce, organisation, talent, leadership, culture, and change plans with defined outcomes, ownership, and measures of success.
  • Understand the site operating model, growth agenda, pipeline, capability requirements, and external talent market, and anticipate people risks and opportunities before they affect delivery.
  • Use constructive challenge, coaching, and influence to strengthen leadership decisions, execution discipline, and accountability, escalating significant risks or strategic issues to the Business HR Manager as appropriate.
  • Lead strategic workforce planning for assigned functions, connecting headcount, skills, organisation design, succession, mobility, and talent acquisition to the site long-range plan.
  • Partner with leaders to design future-fit, scalable organisations with clear roles, decision rights, spans, accountabilities, and capabilities.
  • Identify critical roles and emerging capability needs, and build integrated talent strategies with Talent Acquisition, Talent Management, and other COE partners.
  • Use people data, business metrics, and external insight to frame options, test assumptions, track delivery, and improve the quality and speed of decisions.
  • Support the business in building a strong, diverse talent and succession pipeline for critical roles.
  • Lead Talent Management Reviews, succession discussions, and development planning, ensuring actions translate into stretch assignments, moves, rotations, coaching, and measurable progress.
  • Coach leaders to identify talent beneath the surface, strengthen the feeder pipeline, and make high-quality internal and external talent decisions.
  • Enable leaders to attract, develop, retain, and deploy talent while improving onboarding and transition support for new and promoted leaders.
  • Partner with leaders to define the case for change, build readiness, clarify expectations, and sustain adoption through visible leadership behaviours.
  • Identify opportunities to simplify work, remove roadblocks, and improve speed, quality, and impact.
  • Activate AbbVie Ways We Work and site culture priorities through leader routines, communication, transparent feedback, inclusion, accountability, and recognition.
  • Connect transformation, digitalisation, AI, and process improvement to measurable business outcomes, capability building, and employee experience.
  • Strengthen goal setting, performance differentiation, feedback, calibration, and development conversations by ensuring leaders focus on evidence, outcomes, and behaviours.
  • Coach leaders to address performance early and fairly through clear expectations, timely feedback, and robust improvement plans.
  • Lead and advise on complex employee relations matters, investigations, discipline, grievances, absence, and organisational change in line with Irish employment law, AbbVie policy, and site procedures.
  • Partner with Employee Relations, Legal, Occupational Health, and other specialists where risk or complexity requires escalation.
  • Work as one connected HR team, clarifying ownership and integrating specialist expertise to deliver a consistent, high-quality leader and employee experience.
  • Own the people agenda for assigned client groups while ensuring core HR processes, documentation, controls, and governance are executed accurately and on time.
  • Represent the site on cross-site, regional, and enterprise Business HR initiatives; share learning and adapt enterprise solutions to local business needs.
  • Simplify and continuously improve HR practices, using technology and data to reduce transactional effort and increase time spent on strategic partnership.
Desired Qualifications
  • Experience partnering with senior leaders in a manufacturing, biopharmaceutical, medical device, or similarly regulated environment is strongly preferred.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.